EP3463398A4 - Immune checkpoint inhibitors and cytotoxic t cells for the treatment of cancer - Google Patents
Immune checkpoint inhibitors and cytotoxic t cells for the treatment of cancer Download PDFInfo
- Publication number
- EP3463398A4 EP3463398A4 EP17802270.3A EP17802270A EP3463398A4 EP 3463398 A4 EP3463398 A4 EP 3463398A4 EP 17802270 A EP17802270 A EP 17802270A EP 3463398 A4 EP3463398 A4 EP 3463398A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- cytotoxic
- cancer
- cells
- treatment
- immune checkpoint
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 title 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662341402P | 2016-05-25 | 2016-05-25 | |
PCT/IB2017/000740 WO2017203362A1 (en) | 2016-05-25 | 2017-05-25 | Immune checkpoint inhibitors and cytotoxic t cells for the treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3463398A1 EP3463398A1 (en) | 2019-04-10 |
EP3463398A4 true EP3463398A4 (en) | 2020-03-11 |
Family
ID=60411124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17802270.3A Withdrawn EP3463398A4 (en) | 2016-05-25 | 2017-05-25 | Immune checkpoint inhibitors and cytotoxic t cells for the treatment of cancer |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP3463398A4 (en) |
JP (1) | JP2019516768A (en) |
KR (1) | KR20190028664A (en) |
CN (1) | CN109496155A (en) |
AR (1) | AR108624A1 (en) |
AU (1) | AU2017271128A1 (en) |
CA (1) | CA3023845A1 (en) |
SG (1) | SG11201809541UA (en) |
WO (1) | WO2017203362A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019031939A2 (en) * | 2017-08-10 | 2019-02-14 | 주식회사 굳티셀 | Method for activating t cells for cancer treatment |
WO2020227279A1 (en) * | 2019-05-06 | 2020-11-12 | Hasumi International Research Foundation | Therapy and methods of introducing immature dendritic cells and/or cytotoxic t lymphocyte and anti pd-1 / pd-l1 antibody for treatment of tumors |
CN110452870A (en) * | 2019-05-20 | 2019-11-15 | 河南省肿瘤医院 | A kind of isolated culture method of tumor specific T cells and the product obtained by it |
US20230210984A1 (en) * | 2019-10-23 | 2023-07-06 | The Council Of The Queensland Institute Of Medical Research | Adoptive immunotherapy |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016070136A1 (en) * | 2014-10-31 | 2016-05-06 | Massachusetts Institute Of Technology | Delivery of biomolecules to immune cells |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7794710B2 (en) * | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
EP2133365B1 (en) * | 2006-12-27 | 2017-05-17 | Emory University | Compositions and methods for the treatment of infections and tumors |
US8883500B2 (en) * | 2008-12-05 | 2014-11-11 | Northeastern University | Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy |
AU2012351347B2 (en) * | 2011-12-12 | 2016-05-19 | Baylor College Of Medicine | Process of expanding T cells |
AU2013312211B2 (en) * | 2012-09-07 | 2018-03-29 | King's College London | VISTA modulators for diagnosis and treatment of cancer |
KR20160093012A (en) * | 2013-11-05 | 2016-08-05 | 코그네이트 바이오서비시즈, 인코포레이티드 | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
WO2015157636A1 (en) * | 2014-04-10 | 2015-10-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy |
KR20210032011A (en) * | 2014-09-17 | 2021-03-23 | 더 존스 홉킨스 유니버시티 | Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells |
-
2017
- 2017-05-25 KR KR1020187037498A patent/KR20190028664A/en unknown
- 2017-05-25 CA CA3023845A patent/CA3023845A1/en not_active Abandoned
- 2017-05-25 JP JP2018561725A patent/JP2019516768A/en not_active Withdrawn
- 2017-05-25 SG SG11201809541UA patent/SG11201809541UA/en unknown
- 2017-05-25 EP EP17802270.3A patent/EP3463398A4/en not_active Withdrawn
- 2017-05-25 AU AU2017271128A patent/AU2017271128A1/en not_active Abandoned
- 2017-05-25 WO PCT/IB2017/000740 patent/WO2017203362A1/en unknown
- 2017-05-25 CN CN201780045909.0A patent/CN109496155A/en active Pending
- 2017-05-26 AR ARP170101457A patent/AR108624A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016070136A1 (en) * | 2014-10-31 | 2016-05-06 | Massachusetts Institute Of Technology | Delivery of biomolecules to immune cells |
Non-Patent Citations (5)
Title |
---|
"Current topics in microbiology and immunology", vol. 391, 1 January 2015, SPRINGER BERLIN HEIDELBERG, Berlin, Heidelberg, ISBN: 978-3-540-92165-3, ISSN: 0070-217X, article STEPHEN GOTTSCHALK ET AL: "Adoptive T-Cell Immunotherapy", pages: 427 - 454, XP055286103, DOI: 10.1007/978-3-319-22834-1_15 * |
BOLLARD C M ET AL: "Immunotherapy targeting EBV-expressing lymphoproliferative diseases", BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 21, no. 3, 1 September 2008 (2008-09-01), pages 405 - 420, XP025404482, ISSN: 1521-6926, [retrieved on 20080912], DOI: 10.1016/J.BEHA.2008.06.002 * |
CHUA MELVIN L K ET AL: "Nasopharyngeal carcinoma", LANCET, ELSEVIER, AMSTERDAM, NL, vol. 387, no. 10022, 28 August 2015 (2015-08-28), pages 1012 - 1024, XP029453150, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(15)00055-0 * |
P. COMOLI ET AL: "Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes", JOURNAL OF CLINICAL ONCOLOGY, vol. 23, no. 35, 10 December 2005 (2005-12-10), pages 8942 - 8949, XP055075807, ISSN: 0732-183X, DOI: 10.1200/JCO.2005.02.6195 * |
See also references of WO2017203362A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU2017271128A1 (en) | 2019-01-03 |
AR108624A1 (en) | 2018-09-12 |
CA3023845A1 (en) | 2017-11-30 |
SG11201809541UA (en) | 2018-12-28 |
EP3463398A1 (en) | 2019-04-10 |
WO2017203362A1 (en) | 2017-11-30 |
CN109496155A (en) | 2019-03-19 |
JP2019516768A (en) | 2019-06-20 |
KR20190028664A (en) | 2019-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL272948B1 (en) | Enpp1 inhibitors and their use for the treatment of cancer | |
NZ731467A (en) | Anti-tim3 antibodies and methods of use | |
EP3131544A4 (en) | Mdm2 inhibitors and therapeutic methods using the same | |
EP3494142A4 (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
EP3436002A4 (en) | Pharmaceutical combinations for the treatment of cancer | |
EP3148532A4 (en) | Pharmaceutical combination for the treatment of cancer | |
EP3164157A4 (en) | Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them | |
ZA201900960B (en) | Methods and compositions for the treatment of cancer | |
IL260474B (en) | Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment | |
EP3157336A4 (en) | Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer | |
EP3615056A4 (en) | Methods and agents for the detection and treatment of cancer | |
EP3490561A4 (en) | Combinations for the treatment of cancer | |
IL266486A (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
EP3503887A4 (en) | Combinations for the treatment of cancer | |
EP3463398A4 (en) | Immune checkpoint inhibitors and cytotoxic t cells for the treatment of cancer | |
IL280587B (en) | Flurocytidine derivatives and its composition for the treatment of cancer | |
EP3411122A4 (en) | Cancer vaccines and methods of treatment using the same | |
EP3119427A4 (en) | Methods and materials for treating cancer | |
EP3548007A4 (en) | Methods for the treatment of cancer | |
EP3185910A4 (en) | Methods and compositions for the treatment of cancer | |
EP3119426A4 (en) | Methods and materials for treating cancer | |
EP3363461A4 (en) | Anti-cd43 antibody and use thereof for cancer treatment | |
EP3349731A4 (en) | Combination of topoisomerase-i inhibitors with immunotherapy in the treatment of cancer | |
EP3455761A4 (en) | Methods and materials for staging and treating skin cancer | |
EP3423152A4 (en) | Systems and methods for treatment of fungus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20181225 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20200206 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 5/00 20060101ALI20200131BHEP Ipc: C07K 16/28 20060101ALI20200131BHEP Ipc: A61K 45/06 20060101ALI20200131BHEP Ipc: C12N 5/0783 20100101ALI20200131BHEP Ipc: A61P 35/00 20060101ALI20200131BHEP Ipc: A61K 39/395 20060101ALI20200131BHEP Ipc: A61K 35/17 20150101AFI20200131BHEP Ipc: A61K 38/17 20060101ALI20200131BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20200902 |